Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Genetics · Macrodactyly

Medical Therapies and the PROS Connection

At a Glance

Macrodactyly caused by the PIK3CA-Related Overgrowth Spectrum (PROS) can sometimes be treated with targeted medications like Alpelisib or Sirolimus. These drugs block genetic overgrowth signals but carry serious side effects, so they are typically reserved for widespread or severe PROS cases.

Until recently, surgery was the only way to manage the physical challenges of macrodactyly. However, the discovery that this condition is part of the PIK3CA-Related Overgrowth Spectrum (PROS) has opened the door to targeted therapies—medications designed to “switch off” the specific genetic signal causing the overgrowth [1][2].

For parents, it is vital to understand exactly who these medications are for, as they carry significant side effects and are not standard care for every case of enlarged digits.

Alpelisib (Vijoice): A Targeted Breakthrough

Alpelisib (brand name Vijoice) is the first medication specifically FDA-approved for adults and children (ages 2 and older) with severe or life-threatening manifestations of PROS [3][4].

  • How it Works: In macrodactyly, a mutation in the PIK3CA gene makes the PI3Kα enzyme overactive, acting like a gas pedal that won’t release. Alpelisib is a PI3K inhibitor; it binds to that enzyme and blocks its activity, effectively slowing down the growth signal [2][5].
  • Who Qualifies?: It is important to note that Alpelisib is typically reserved for children with widespread, complex, or life-threatening PROS conditions (like CLOVES syndrome). Isolated macrodactyly (where only a finger or toe is enlarged without other systemic involvement) rarely meets this threshold [6][3]. This drug is incredibly expensive, carries serious toxicities, and is not a simple alternative to surgery for localized overgrowth.

Managing Side Effects: The Sugar Connection

Because PI3Kα also plays a role in how the body processes insulin, Alpelisib can cause hyperglycemia (high blood sugar) [7][8]. This is a severe side effect that requires proactive management.

  • Pediatric Management: If a child develops hyperglycemia on Alpelisib, a pediatric endocrinologist must be involved immediately [8]. Management in children relies on dietary adjustments, reducing the medication dose, or occasionally using insulin [8].
  • (Note: While adults might use medications called SGLT2 inhibitors for this, they are generally not approved or safe for young children due to the risk of a dangerous condition called diabetic ketoacidosis [7][9].)
  • Other Side Effects: Parents may also see skin rashes or mouth sores, which are typically managed with topical creams or temporary dose adjustments [8][10].

Other Options: Sirolimus

Before Alpelisib was available, Sirolimus (also known as Rapamune) was the primary medical option [11].

  • mTOR Inhibition: Sirolimus works further “downstream” in the growth pathway by inhibiting a protein called mTOR [12].
  • The Difference: While Sirolimus is very effective for stabilizing certain types of overgrowth—particularly lymphatic or vascular malformations—it is generally less specific for the PIK3CA mutation than Alpelisib [13][14]. It may help stabilize growth but rarely shrinks existing bony or fatty overgrowth in macrodactyly [11].

The Role of Medical Therapy in Your Child’s Care

Medical therapy is rarely a “quick fix.” It is an intense, long-term commitment that requires frequent blood tests and specialist monitoring to ensure the dose is safe and effective [15][16]. Always speak extensively with a geneticist to evaluate the risk versus reward of medication for your child’s specific case.

Common questions in this guide

What medications are used to treat macrodactyly?
Targeted therapies like Alpelisib (Vijoice) and Sirolimus (Rapamune) are sometimes used for macrodactyly when it is part of the broader PIK3CA-Related Overgrowth Spectrum (PROS). These medications help slow down the genetic signals causing the overgrowth.
Will Alpelisib shrink my child's isolated enlarged finger?
Alpelisib is generally reserved for complex, widespread, or life-threatening cases of PROS. It is rarely used to treat an isolated enlarged finger or toe due to the high cost and serious side effects associated with the drug.
What are the side effects of Alpelisib?
Because the targeted enzyme is involved in how the body processes insulin, Alpelisib can cause severe high blood sugar (hyperglycemia). Children may also experience skin rashes or mouth sores while taking the medication.
How is high blood sugar managed in children taking Alpelisib?
If your child develops high blood sugar while taking Alpelisib, a pediatric endocrinologist must be involved. They will typically manage the condition using dietary adjustments, reducing the medication dose, or occasionally prescribing insulin.
How is Sirolimus different from Alpelisib for PROS?
Sirolimus targets a different part of the cellular growth pathway called mTOR. While it is effective for stabilizing certain types of overgrowth, it is less specific to the PIK3CA mutation than Alpelisib and rarely shrinks existing bony or fatty tissue.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my child's localized macrodactyly meet the clinical criteria for severe or widespread PROS to qualify for targeted therapies like Alpelisib?
  2. 2.What is the baseline screening process for blood sugar and A1C before starting any PI3K inhibitor?
  3. 3.If my child develops hyperglycemia, how will the pediatric endocrinologist manage it, and what are the signs I should watch for?
  4. 4.How does the effectiveness of Sirolimus compare to Alpelisib for my child's specific case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    An Analysis of the Pathogenic Genes and Mutation Sites of Macrodactyly.

    Li JF, Tian GL, Pan H, et al.

    Pharmacogenomics and personalized medicine 2022; (15()):55-64 doi:10.2147/PGPM.S346373.

    PMID: 35125881
  2. 2

    Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).

    Canaud G, Lopez Gutierrez JC, Irvine AD, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2023; (25(12)):100969 doi:10.1016/j.gim.2023.100969.

    PMID: 37634128
  3. 3

    FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.

    Singh S, Bradford D, Li X, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(1)):23-28 doi:10.1158/1078-0432.CCR-23-1270.

    PMID: 37624421
  4. 4

    PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib.

    Pagliazzi A, Oranges T, Traficante G, et al.

    Frontiers in pediatrics 2021; (9()):732836 doi:10.3389/fped.2021.732836.

    PMID: 34568242
  5. 5

    Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model.

    Mohan AM, Prasad S, Schmitz-Peiffer F, et al.

    Endocrine-related cancer 2024; (31(1)).

    PMID: 37943630
  6. 6

    Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.

    Wenger TL, Ganti S, Bull C, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(11)):2318-2328 doi:10.1016/j.gim.2022.07.026.

    PMID: 36066547
  7. 7

    SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.

    Borrego MR, Lu YS, Reyes-Cosmelli F, et al.

    Breast cancer research and treatment 2024; (208(1)):111-121 doi:10.1007/s10549-024-07405-8.

    PMID: 39177931
  8. 8

    Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.

    Rugo HS, André F, Yamashita T, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2020; (31(8)):1001-1010 doi:10.1016/j.annonc.2020.05.001.

    PMID: 32416251
  9. 9

    SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.

    Sahakian N, Cattieuw L, Ramillon-Cury C, et al.

    Clinical diabetes and endocrinology 2021; (7(1)):17 doi:10.1186/s40842-021-00125-8.

    PMID: 34281618
  10. 10

    A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib.

    Lin Y, Zheng X, Chen Y, et al.

    Heliyon 2024; (10(6)):e27529 doi:10.1016/j.heliyon.2024.e27529.

    PMID: 38496864
  11. 11

    Old treatments for new genetic conditions: Sirolimus therapy in a child affected by mosaic overgrowth with fibroadipose hyperplasia.

    Leoni C, Onesimo R, Resta N, et al.

    Clinical genetics 2019; (96(1)):102-103 doi:10.1111/cge.13550.

    PMID: 31012097
  12. 12

    Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer.

    McAndrew NP, Finn RS

    JCO oncology practice 2022; (18(5)):319-327 doi:10.1200/OP.21.00384.

    PMID: 34637323
  13. 13

    The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells.

    Kirstein AS, Augustin A, Penke M, et al.

    Cancers 2019; (11(10)) doi:10.3390/cancers11101586.

    PMID: 31627436
  14. 14

    Medical Therapies for Pediatric Lymphatic Malformations: A Systematic Review.

    Hollman D, Cheema H, Yu AC, et al.

    Journal of cutaneous medicine and surgery 2026; (30(3)):259-264 doi:10.1177/12034754251386785.

    PMID: 41170851
  15. 15

    Alpelisib in pediatric PIK3CA- and TIE-2-mutant vascular anomalies: a case series on safety, efficacy, and drug exposure.

    Etingin A, Remy A, Sonea T, et al.

    Pediatric hematology and oncology 2025; (42(4)):228-241 doi:10.1080/08880018.2025.2498660.

    PMID: 40346819
  16. 16

    Fixed dosing of alpelisib for children with vascular anomalies: Can we do better?

    Remy A, Etingin A, Gavra P, et al.

    British journal of clinical pharmacology 2025; (91(3)):914-920 doi:10.1111/bcp.16388.

    PMID: 39854034

This page explains medical therapies for PROS and macrodactyly for educational purposes. Always consult your pediatric geneticist and endocrinologist to evaluate the risks and benefits of medication for your child's specific case.

Get notified when new evidence is published on Macrodactyly of fingers.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.